Kannangara Ajith P, Levitan Denise, Fleischer Alan B
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
J Drugs Dermatol. 2010 Aug;9(8):1017-8.
Topical 5-fluorouracil (5-FU) has been used in the treatment of various benign and malignant tumors of the skin, but only few address its therapeutic value on cutaneoues T-cell lymphoma. (CTCL). The authors report six cases of early stage CTCL responded to topical 5-FU. All of these patients (four females and two males) with early stage CTCL (1A = 4; 18 = 1; 2B = 1) had good response to topical 5-FU following three to 18 months' treatment. Four patients achieved complete response (CR) and two patients responded partially (PR). Tolerance to the treatment was good, with the exception of mild irritation, with no patients reporting serious side effects. The overall efficacy, relatively modest price and low incidence of side effects indicate that topical 5-FU has a place for treatment of early stage CTCL.
外用5-氟尿嘧啶（5-FU）已用于治疗各种皮肤良恶性肿瘤，但仅有少数研究涉及其对皮肤T细胞淋巴瘤（CTCL）的治疗价值。作者报告了6例早期CTCL患者对外用5-FU有反应。所有这些早期CTCL患者（4名女性和2名男性，1A期 = 4例；1B期 = 1例；2B期 = 1例）在接受3至18个月的治疗后，对外用5-FU均有良好反应。4例患者达到完全缓解（CR），2例患者部分缓解（PR）。除轻度刺激外，治疗耐受性良好，无患者报告严重副作用。总体疗效、相对适中的价格和低副作用发生率表明外用5-FU在早期CTCL的治疗中占有一席之地。
